Tabrecta Approved for Metastatic NSCLC on Confirmatory Data
The FDA has granted regular approval to Tabrecta (capmatinib) for the treatment of adults with metastatic NSCLC with MET exon 14 skipping.
Stay updated with breaking news from Accessed August. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has granted regular approval to Tabrecta (capmatinib) for the treatment of adults with metastatic NSCLC with MET exon 14 skipping.
15.08.2022 - Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Guardant Reveal, the only tissue-free test for the detection of residual and recurrent disease for colorectal cancer (CRC), is now available for patients ...
The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for previously treated adults with HER2-mutated unresectable or metastatic NSCLC.
The FDA has approved Nubeqa (darolutamide) plus docetaxel for the treatment of metastatic hormone-sensitive prostate cancer.
The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for previously treated adults with HER2-mutated unresectable or metastatic NSCLC.